Post

New research · Ophthalmology
Immunologic research · 18h
Systematic reviewImmunologic research · 2026

Antineutrophil cytoplasmic antibody-associated pachymeningitis: a systematic review of clinical features, diagnosis and treatment outcomes.

Graziella Aguiar Santos Faria, Paula Baleeiro Rodrigues Silva, Gabriela Abrahão Allioni … Guilherme Diogo Silva
Read paper
OphthalmologySystematic review

Nearly a quarter of patients with antineutrophil cytoplasmic antibody-associated pachymeningitis relapsed after treatment.

Antineutrophil cytoplasmic antibody-associated pachymeningitis: a systematic review of clinical features, diagnosis and treatment outcomes.

Graziella Aguiar Santos Faria … Guilherme Diogo Silva
Immunologic research · 2026
Background

Antineutrophil cytoplasmic antibody (antineutrophil cytoplasmic antibody)-associated pachymeningitis is a rare inflammatory disorder of the dura mater that may occur in isolation or as part of systemic vasculitis.

Purpose

We aimed to synthesize clinical presentation, investigations, and treatment outcomes to improve diagnosis and guide management.

Methods

We identified 230 patients from 177 reports, including 108 myeloperoxidase-antineutrophil cytoplasmic antibody-positive, 71 PR3-antineutrophil cytoplasmic antibody-positive, and 3 dual myeloperoxidase/PR3-positive cases; 46 antineutrophil cytoplasmic antibody-positive cases had unspecified antigen specificity, and 2 were ELISA-negative but antineutrophil cytoplasmic antibody IIF-positive.

n = 230 patients
23.5%
Results
23.5%
About 1 in 4 patients had disease relapse after treatment, at median 9-month follow-up.
n = 230 patients
More results

Median age was 60 years; 53% were male.

Systemic involvement was present in 89% of cases, primarily affecting the ear, nose, throat, lungs, orbits and kidneys.

Inflammatory markers were raised in > 90%, and cerebrospinal fluid pleocytosis in 50%.

More results

Rituximab (25%) was associated with lower rates of refractory disease.

“
Conclusion

Relapse and incomplete recovery remain common despite treatment, underscoring the need for early recognition, targeted immunotherapy, and long-term follow-up.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving